Market revenue in 2023 | USD 13.3 million |
Market revenue in 2030 | USD 22.8 million |
Growth rate | 8% (CAGR from 2023 to 2030) |
Largest segment | Small molecule |
Fastest growing segment | Large Molecule |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Small Molecule, Large Molecule |
Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Small molecule was the largest segment with a revenue share of 63.91% in 2024. Horizon Databook has segmented the Saudi Arabia in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
Establishment of universities focused on biotechnology and increase in the number of clinical research organizations with proven track records of conducting clinical trials are driving the in vivo CRO market growth in Saudi Arabia.
Moreover, an increase in the number of properly-trained investigators, rapidly growing healthcare investments, and presence of numerous world-class medical facilities are some factors expected to propel the in vivo CRO market growth over the forecast period.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account